Does treated primary hypertension lead to end-stage renal disease? A 20-year follow-up of the primary prevention study in Goteborg, Sweden

Nephrology Dialysis Transplantation

Volumn 13, Issue 12, 1998, Pages 3084-3090

  Siewert Delle, Annica ^a   Ljungman, Susanne ^a   Andersson, Ove K ^a   Wilhelmsen, Lars ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antihypertensive treatment; Epidemiology; Population based; Primary hypertension; Renal function

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; EUROPE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DISEASE; MALE; NORMAL HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RENOVASCULAR DISEASE; SWEDEN; UNITED STATES; URINARY TRACT DISEASE;

EID: 0031727465     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.12.3084     Document Type: Article

References (30)

1. Zucchclli P, Zuccalà A. Can we accurately diagnose nephrosclerosis? Nephrol Dial Transplant 1995; 10 [Suppl. 6]: 2 5
2. Brunner FP, Selwood NH, on behalf of the EDTA Registration Committee. Profile of patients on RRT in Europe and death rates due to major causes of death groups. Kidney Int 1992; 42 [Suppl. 38]: S4-15
3. US Renal data system, in USRDS 1997 Annual Data Report. The national institutes of Health, The National Institute of Diabetes and Digestive and Kidney Diseases. Division of Kidney, Urologic, and Hematologic Disease, 1997
4. Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955; 1: 33-42
5. Woods JE. Renal function in essential hypertension. Semin Nephrol 1983; 3: 30-39
6. Hartford M, Wendelhag I, Berglund G, Wallentin I, Ljungman S, Wikstrand J. Cardiovascular and renal effects of long-term antihypertensive treatment. JAMA 1988; 259: 2553-2557
7. Pettinger WA, Lee HC, Reisch J, Mitchell HC. Long-term improvement in renal function after short term strict blood pressure control in hypertensive nephrosclerosis. Hypertension 1989; 13: 766 772
8. Siewert-Delle A, Ljungman S, Hartford M, Wikstrand J. Effects of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension. Am J Hypertens 1996; 9: 841 849
9. Siewert-Delle A, Ljungman S, Hartford M, Wikstrand J. Effects of intensified blood pressure reduction on renal function and albumin excretion in primary hypertension Addition of Felodipine or Ramipril to long-term treatment with β-blockade. Am J Hypertens 1995; 8: 113-123
10. Aurell M, Bengtsson C, Björck S. Enalapril versus metoprolol in primary hypertension-effects on the glomerular filtration rate. Nephrol Dial Transplant 1997; 2: 2289 2294
11. Schulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. Hypertension 1989; 13 [Suppl. 1]: 80 93
12. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J 1986; 7: 279-288
13. Wilhelmsen L, Ljungberg S, Wedel H, Werkö L. A comparison between participants and non-participants in a primary preventive trial. J Chron Dis 1976; 29: 331-339
14. Wilhelmsen L, Berglund G, Werkö L. Prevalence and management of hypertension in a general population sample of Swedish men. Prev Med 1973; 2: 57-66
15. Wilhelmsen L, Tibblin G, Werkö L. A primary preventive study in Gothenburg, Sweden. Prev Med 1972; 1: 153 160
16. Andersson O, Berglund G, Hansson L et al. Organisation and efficacy of an out-patient hypertension clinic. Acta Med Scand 1978; 203: 391-398
17. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 1976; 2: 554-556
18. Samuelsson O. Hypertension in middle-aged men. Management, morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand 1985 [Suppl. 702] 1-79
19. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967; 202: 1028-1034
20. Collins R, Peto R, MacMahon S et al. Epidemiology. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838
21. Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int 1992; 41 [Suppl 36]: S33-37
22. Laragh JH and Brenner BM. Hypertension - Pathophysiology, Diagnosis, and Management. Raven Press, New York, 1995; 433-443
23. Tobian L. Does essential hypertension lead to renal failure. Am J Cardiol 1987; 60 [Suppl. I]: 42-46
24. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984; 26: 861-868
25. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 320: 684-688
26. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 1982; 306: 1276-1279
27. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 1988; 12: 285 290
28. Levy SB, Talner LB, Coel MN et al. Renal vasculature in essential hypertension: Racial differences. Ann Intern Med 1978; 88: 12-16
29. Entwisle G, Apostolides AY, Hebel J et al. Target organ damage in black hypertensives. Circulation 1977; 55: 792-796
30. Hypertension control: report of a WHO expert committee. Technical Report Series/World Health Organisation; 862 Geneva 1996